AIMS: Thiazolidinediones (TZDs) not only enhance cellular glucose transport but are reported to have potent anti-inflammatory effects. These effects may play an important role in the insulin sensitizing mechanism, and possibly precede the effects on parameters of glucoregulation. We sought to investigate whether these anti-inflammatory effects could yield early responding biomarkers for TZD action in Type 2 diabetes mellitus (T2DM) patients and healthy volunteers (HV) to expedite early clinical development of novel compounds. METHODS: We investigated the timing of treatment effects on several proinflammatory cytokines and markers of inflammation in comparison with effects on typical measures of glucoregulation in T2DM patients and HV receivingrosiglitazone 4 mg or placebo twice daily for 6 weeks. RESULTS: We found a significant reduction in interleukin (IL)-6 [-39.4%, confidence interval (CI) - 60.0, - 8.2] and white blood cell count (-18.4%, CI - 30.2, - 4.5) after 4 weeks of treatment in the T2DM group. These anti-inflammatory effects did not precede the effects on typical parameters of glucoregulation in the T2DM group and there was no significant anti-inflammatory response in the HV group. CONCLUSION: We could not identify biomarkers that precede the effects of rosiglitazone on parameters of glucoregulation in T2DM or that have a significant response in HV. However, the IL-6 response observed in this study indicates a potential role for this cytokine as complementary biomarker in clinical 'proof of concept' studies with novel TZDs.
RCT Entities:
AIMS: Thiazolidinediones (TZDs) not only enhance cellular glucose transport but are reported to have potent anti-inflammatory effects. These effects may play an important role in the insulin sensitizing mechanism, and possibly precede the effects on parameters of glucoregulation. We sought to investigate whether these anti-inflammatory effects could yield early responding biomarkers for TZD action in Type 2 diabetes mellitus (T2DM) patients and healthy volunteers (HV) to expedite early clinical development of novel compounds. METHODS: We investigated the timing of treatment effects on several proinflammatory cytokines and markers of inflammation in comparison with effects on typical measures of glucoregulation in T2DM patients and HV receiving rosiglitazone 4 mg or placebo twice daily for 6 weeks. RESULTS: We found a significant reduction in interleukin (IL)-6 [-39.4%, confidence interval (CI) - 60.0, - 8.2] and white blood cell count (-18.4%, CI - 30.2, - 4.5) after 4 weeks of treatment in the T2DM group. These anti-inflammatory effects did not precede the effects on typical parameters of glucoregulation in the T2DM group and there was no significant anti-inflammatory response in the HV group. CONCLUSION: We could not identify biomarkers that precede the effects of rosiglitazone on parameters of glucoregulation in T2DM or that have a significant response in HV. However, the IL-6 response observed in this study indicates a potential role for this cytokine as complementary biomarker in clinical 'proof of concept' studies with novel TZDs.
Authors: P Ebeling; A M Teppo; H A Koistinen; J Viikari; T Rönnemaa; M Nissén; S Bergkulla; P Salmela; J Saltevo; V A Koivisto Journal: Diabetologia Date: 1999-12 Impact factor: 10.122
Authors: G D Tan; B A Fielding; J M Currie; S M Humphreys; M Désage; K N Frayn; M Laville; H Vidal; F Karpe Journal: Diabetologia Date: 2004-12-24 Impact factor: 10.122
Authors: H Ghanim; R Garg; A Aljada; P Mohanty; Y Kumbkarni; E Assian; W Hamouda; P Dandona Journal: J Clin Endocrinol Metab Date: 2001-03 Impact factor: 5.958
Authors: Martijn van Doorn; Jack Vogels; Albert Tas; Ewoud Jan van Hoogdalem; Jacobus Burggraaf; Adam Cohen; Jan van der Greef Journal: Br J Clin Pharmacol Date: 2007-05 Impact factor: 4.335
Authors: Marilyn J Hammer; Corey Casper; Ted A Gooley; Paul V O'Donnell; Michael Boeckh; Irl B Hirsch Journal: Biol Blood Marrow Transplant Date: 2009-03 Impact factor: 5.742
Authors: Pamela M Rogers; Nazar Mashtalir; Miloni A Rathod; Olga Dubuisson; Zhong Wang; Kumar Dasuri; Scott Babin; Alok Gupta; Nathan Markward; William T Cefalu; Nikhil V Dhurandhar Journal: Diabetes Date: 2008-07-03 Impact factor: 9.461
Authors: Omar S Al-Attas; Nasser M Al-Daghri; Khalid Al-Rubeaan; Nancy F da Silva; Shaun L Sabico; Sudhesh Kumar; Philip G McTernan; Alison L Harte Journal: Cardiovasc Diabetol Date: 2009-04-15 Impact factor: 9.951
Authors: Behnam Saremi; Sarah Winand; Paula Friedrichs; Asako Kinoshita; Jürgen Rehage; Sven Dänicke; Susanne Häussler; Gerhard Breves; Manfred Mielenz; Helga Sauerwein Journal: PLoS One Date: 2014-01-21 Impact factor: 3.240